, TLR3 immunity to infection in mice and humans, vol.25, pp.19-33, 2013.
Trial Watch: Toll-like receptor agonists for cancer therapy, OncoImmunology, vol.2, p.25238, 2013. ,
Toll-like receptors and cancer, Nat. Rev. Cancer, vol.9, pp.57-63, 2009. ,
TLR3 can directly trigger apoptosis in human cancer cells, J. Immunol, vol.176, pp.4894-4901, 2006. ,
Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma, Clin. Cancer Res, vol.13, pp.5703-5709, 2007. ,
Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas, Immunology, vol.128, pp.600-611, 2009. ,
Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic, Infect. Agents Cancer, vol.7, p.36, 2012. ,
Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism, Carcinogenesis, vol.29, pp.1334-1342, 2008. ,
TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production, J. Immunol, vol.182, pp.4471-4478, 2009. ,
dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8, Cell Death Differ, vol.19, pp.1482-1494, 2012. ,
Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis, Cell Death Dis, vol.9, p.874, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01871291
Leverkus, cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms, Mol. Cell, vol.43, pp.449-463, 2011. ,
Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array, Hum. Pathol, vol.55, pp.72-82, 2016. ,
BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas, J. Thorac. Oncol, vol.12, pp.724-733, 2017. ,
Novel therapies for malignant pleural mesothelioma, Lancet Oncol, vol.19, pp.161-172, 2018. ,
French Cooperative Thoracic I. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial, Lancet Oncol, vol.20, pp.239-253, 2019. ,
French Network for Rare Peritoneal, Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: multi-Institutional Retrospective Study, Eur. J. Cancer, vol.65, pp.69-79, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01368938
, Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas, vol.52, pp.9-18, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01792622
Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am. J. Pathol, vol.178, pp.1033-1042, 2011. ,
Cleaved/associated TLR3 represents the primary form of the signaling receptor, J. Immunol, vol.190, pp.764-773, 2013. ,
Toll-like receptor 3 signal in dendritic cells benefits cancer immunotherapy, Front. Immunol, vol.8, p.1897, 2017. ,
Recognition of doublestranded RNA and activation of NF-kappaB by Toll-like receptor 3, Nature, vol.413, pp.732-738, 2001. ,
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses, Nature, vol.441, pp.101-105, 2006. ,
Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3, Mol. Cell, vol.54, pp.133-146, 2014. ,
Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells, Cancer Res, vol.68, pp.4511-4517, 2008. ,
Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells, Clin. Cancer Res, vol.9, pp.4255-4266, 2003. ,
Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression, Int. J. Cancer, vol.88, pp.986-991, 2000. ,
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis, Cell, vol.131, pp.669-681, 2007. ,
Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis, Cell, vol.94, pp.491-501, 1998. ,
The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells, Cancer Res, vol.72, pp.3948-3957, 2012. ,
Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity, J. Natl. Cancer Inst, vol.89, pp.783-789, 1997. ,
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo, Cancer Res, vol.60, pp.847-853, 2000. ,
Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma, Int. J. Cancer, vol.118, pp.230-242, 2006. ,
Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP, Mol. Cancer Ther, vol.4, pp.2026-2036, 2005. ,
Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells, Cell Death Differ, vol.17, pp.942-951, 2010. ,
Dying cells actively regulate adaptive immune responses, Nat. Rev. Immunol, vol.17, pp.262-275, 2017. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01491773
Clearance of apoptotic and necrotic cells and its immunological consequences, Apoptosis, vol.11, pp.1709-1726, 2006. ,
RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells, Science, vol.350, pp.328-334, 2015. ,
Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, vol.22, pp.7265-7279, 2003. ,
Dimanche-Boitrel, Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs, J. Biol. Chem, vol.274, pp.7987-7992, 1999. ,
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway, Clin. Cancer Res, vol.6, pp.203-212, 2000. ,
The TLR3 agonist inhibit drug efflux and sequentially consolidates low-dose cisplatinbased chemoimmunotherapy while reducing side effects, Mol. Cancer Ther, vol.16, pp.1068-1079, 2017. ,
Radiosensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2, Cell. Oncol, vol.42, pp.29-40, 2019. ,
Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo, Nat. Commun, vol.6, p.6280, 2015. ,
Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100, Clin. Dev. Immunol, vol.2013, p.283649, 2013. ,